# Anti-CRISPR AcrF8 in Pectobacterium Phage ZF40: Mechanism, Structure, and Regulation

Editorial note: see also the reviews of the related gene in the same species in <../ACA2/ACA2-deep-research.md>

For comparison, see also the gemini-generated: <ACA2-deep-research-gemini.md>


## Background and Role in Phage Infection

AcrIF8 (also known as AcrF8) is an anti-CRISPR protein encoded by *Pectobacterium carotovorum* temperate phage ZF40. It is a small protein (\~92 amino acids) belonging to the Type I-F anti-CRISPR family[\[1\]](https://en.wikipedia.org/wiki/Anti-CRISPR#:~:text=AcrF8%20%20AcrF8%20ZF40%20,II%E2%80%91A%20%20149). The role of AcrF8 is to protect phage ZF40 from the host bacterium’s Type I-F CRISPR-Cas immune system, enabling successful infection and lysogeny[\[2\]](https://www.liebertpub.com/doi/10.1089/crispr.2024.0047#:~:text=,replication%2C%20and%20that%20recombination). In fact, phage ZF40 carries the **acrIF8** gene in an operon adjacent to an *anti-CRISPR associated* gene called **aca2**, a genetic arrangement commonly seen in anti-CRISPR loci[\[3\]](https://pmc.ncbi.nlm.nih.gov/articles/PMC8434428/#:~:text=et%20al,CRISPR%20production). This acrIF8–aca2 operon is critical for phage survival: it acts to block the host’s CRISPR interference, allowing the phage genome to replicate and persist without being cleaved by Cas nucleases[\[2\]](https://www.liebertpub.com/doi/10.1089/crispr.2024.0047#:~:text=,replication%2C%20and%20that%20recombination). AcrF8 was originally identified through bioinformatic analysis of such operons – the discovery of Aca2 (a putative transcriptional regulator) led to the prediction of five new Type I-F anti-CRISPR proteins (AcrF6–AcrF10, including AcrF8) encoded in phage/prophage genomes of various Proteobacteria[\[4\]](https://en.wikipedia.org/wiki/Anti-CRISPR#:~:text=After%20some%20studies%2C%20a%20similar,6)[\[5\]](https://en.wikipedia.org/wiki/Anti-CRISPR#:~:text=to%20their%20genomic%20proximity%3A%20AcrF6%2C,6).

## Mechanism of CRISPR-Cas Inhibition by AcrF8

AcrF8 is an inhibitor that **acts directly on the CRISPR-Cas surveillance complex** (Cascade) to prevent DNA targeting. Notably, structural studies revealed that AcrF8 uses a *unique mode of action* not seen in other anti-CRISPRs: it binds the Cascade complex and directly contacts the CRISPR RNA (crRNA) within the complex[\[6\]](https://pmc.ncbi.nlm.nih.gov/articles/PMC7132274/#:~:text=proteins%20bind%20differently%20to%20the,F%20CRISPR%E2%80%93Cas%20system). In the Type I-F system, the crRNA-guided Cascade (also called the Csy complex) is composed of Cas5f, Cas6f, multiple Cas7f subunits, a large subunit Cas8f, and the crRNA; this complex recognizes foreign DNA and recruits Cas2/3 to cleave it[\[7\]](https://pmc.ncbi.nlm.nih.gov/articles/PMC7132274/#:~:text=I%20CRISPR%E2%80%93Cas%20systems%20are%20further,complex%20is%20comprised%20of%20four)[\[8\]](https://pmc.ncbi.nlm.nih.gov/articles/PMC7132274/#:~:text=types%20of%20Cas%20proteins%20%28Cas5f,1%7D%20%284). AcrF8 targets this interference step.

Using cryo-electron microscopy, researchers solved the structure of AcrF8 bound to a Type I-F Cascade and **uncovered how AcrF8 blocks the immune complex**[\[9\]](https://pmc.ncbi.nlm.nih.gov/articles/PMC7132274/#:~:text=AcrF8%20is%20a%2092,just%20after%20the%20kink%20caused). AcrF8 inserts itself into a cavity on the “spiral backbone” of Cascade, nestled among the Cas5f, Cas7f, and Cas8f proteins[\[10\]](https://pmc.ncbi.nlm.nih.gov/articles/PMC7132274/#:~:text=AcrF8%20is%20a%2092,4%20%C3%85%2C%20which%20is%20close). In this position, AcrF8 makes multiple contacts with the **crRNA** and the Cascade proteins. In particular, a cluster of AcrF8 residues (Thr29, Ile31, Ala32, Asn33) is positioned within \~4 Å of a stretch of three crRNA nucleotides (corresponding to bases U\_+21, U\_+22, G\_+23 on the crRNA)[\[11\]](https://pmc.ncbi.nlm.nih.gov/articles/PMC7132274/#:~:text=residue,crRNA%20hybridization%20and). These contacts include hydrogen bonds and other non-bonded interactions that tether AcrF8 to the crRNA[\[11\]](https://pmc.ncbi.nlm.nih.gov/articles/PMC7132274/#:~:text=residue,crRNA%20hybridization%20and). By binding the crRNA at this location – just downstream of a natural kink in the RNA formed by the Cas7.5f “thumb” domain – AcrF8 effectively **occludes about four nucleotides of the crRNA**[\[12\]](https://pmc.ncbi.nlm.nih.gov/articles/PMC7132274/#:~:text=nucleotides%20%28U,this%20hypothesis%2C%20we%20recombinantly%20expressed). This occlusion means that the protected segment of the crRNA cannot base-pair with the complementary protospacer DNA, *thereby preventing formation of the RNA–DNA hybrid (R-loop)* needed for target recognition and cleavage[\[13\]](https://pmc.ncbi.nlm.nih.gov/articles/PMC7132274/#:~:text=nucleotides%20%28U,we%20also%20observed%20interactions%20between). In essence, AcrF8 “plugs” the Cascade complex in a way that stops the CRISPR interference reaction at the stage of crRNA–target hybridization. Without a proper R-loop, the nuclease-helicase Cas2/3 cannot be recruited to degrade the invader DNA, so the phage DNA evades destruction[\[14\]](https://pmc.ncbi.nlm.nih.gov/articles/PMC7132274/#:~:text=C%29,we%20also%20observed%20interactions%20between).

Experimental evidence supports this mechanism. Mutagenesis of the AcrF8 residues that contact the crRNA disrupts its anti-CRISPR function. For example, substituting Ala for I31 or Gly for A32 (two residues in the crRNA-binding region of AcrF8) caused the Cascade complex to regain DNA cleavage activity, as compared to wild-type AcrF8 which completely inhibited cleavage[\[14\]](https://pmc.ncbi.nlm.nih.gov/articles/PMC7132274/#:~:text=C%29,we%20also%20observed%20interactions%20between). In other words, AcrF8 mutants defective in binding that crRNA segment could no longer block the CRISPR-Cas – the host nuclease was able to cut DNA when those key AcrF8–RNA contacts were lost[\[15\]](https://pmc.ncbi.nlm.nih.gov/articles/PMC7132274/#:~:text=by%20the%20thumb%20of%20Cas7,we%20also%20observed%20interactions%20between). This result confirms that **AcrF8’s anti-CRISPR activity critically depends on its interface with the crRNA**, which is necessary to halt R-loop formation and subsequent DNA degradation[\[14\]](https://pmc.ncbi.nlm.nih.gov/articles/PMC7132274/#:~:text=C%29,we%20also%20observed%20interactions%20between). Notably, other Type I-F Acr proteins employ different strategies (for instance, AcrIF1, AcrIF2, AcrIF6, and AcrIF10 bind Cascade at other sites, and AcrIF3 targets the Cas3 nuclease[\[16\]](https://www.frontiersin.org/journals/bioengineering-and-biotechnology/articles/10.3389/fbioe.2020.575393/full#:~:text=AcrIF8,of%20AcrIF4%20is%20still%20unknown)), but **AcrF8’s strategy of blocking the crRNA–DNA hybrid is distinct**[\[6\]](https://pmc.ncbi.nlm.nih.gov/articles/PMC7132274/#:~:text=proteins%20bind%20differently%20to%20the,F%20CRISPR%E2%80%93Cas%20system)[\[17\]](https://www.frontiersin.org/journals/bioengineering-and-biotechnology/articles/10.3389/fbioe.2020.575393/full#:~:text=are%20Cas7%20,work%20by%20mimicking%20the). By binding the Cas7f backbone (which is essential for crRNA positioning)[\[18\]](https://www.frontiersin.org/journals/bioengineering-and-biotechnology/articles/10.3389/fbioe.2020.575393/full#:~:text=subunits%20can%20share%20similar%20inhibitory,work%20by%20mimicking%20the), AcrF8 uniquely interferes at the earliest stage of interference – an elegant solution evolved by phage ZF40 to disarm the host’s adaptive immunity.

## Structural Features and Functional Domains of AcrF8

AcrF8 is a single-domain protein with a compact **α/β fold**. Despite its small size, it contains both β-sheet and α-helical elements, similar to several other Type I-F anti-CRISPR proteins[\[19\]](https://pmc.ncbi.nlm.nih.gov/articles/PMC7132274/#:~:text=Our%20near,the%20big%20difference%20being%20in). (By comparison, some Acr proteins like AcrF6 are purely helical, but AcrF8, AcrF9, AcrF10, etc., have mixed secondary structure motifs forming a stable α/β core[\[20\]](https://pmc.ncbi.nlm.nih.gov/articles/PMC7132274/#:~:text=The%20100,Cas8f%20has%20been%20shown%20to)[\[19\]](https://pmc.ncbi.nlm.nih.gov/articles/PMC7132274/#:~:text=Our%20near,the%20big%20difference%20being%20in).) Structural analysis showed that AcrF8’s β-sheet and loop regions form the primary interface with the Cascade, while an α-helix of AcrF8 also plays a crucial role in docking to the complex[\[21\]](https://pmc.ncbi.nlm.nih.gov/articles/PMC7132274/#:~:text=structures%20shows%20that%20they%20share,hydrophobic%20surface%20to%20promote%20the)[\[22\]](https://pmc.ncbi.nlm.nih.gov/articles/PMC7132274/#:~:text=surrounded%20by%20Cas5f%2C%20Cas7,4%20%C3%85%2C%20which%20is%20close). In the Cascade-bound conformation, a prominent helix of AcrF8 lies against a positively charged pocket on the Cascade surface[\[22\]](https://pmc.ncbi.nlm.nih.gov/articles/PMC7132274/#:~:text=surrounded%20by%20Cas5f%2C%20Cas7,4%20%C3%85%2C%20which%20is%20close). Specifically, basic residues from the host Cas proteins – Lys76 of Cas5f, Lys257 of the Cas7.6f subunit, and Arg210/Lys216 of Cas8f – form a patch that grips this helix of AcrF8 via electrostatic and hydrogen-bond contacts[\[22\]](https://pmc.ncbi.nlm.nih.gov/articles/PMC7132274/#:~:text=surrounded%20by%20Cas5f%2C%20Cas7,4%20%C3%85%2C%20which%20is%20close). This interaction likely helps anchor AcrF8 in the correct orientation within the Cascade. In addition, AcrF8 makes a contact through Thr43 with the Cas7.5f subunit (notably with Cas7.5f residues Leu94 and Lys260)[\[23\]](https://pmc.ncbi.nlm.nih.gov/articles/PMC7132274/#:~:text=AcrF8%20%28Fig,crRNA%20hybrid%20%28Fig.%203%20B). This contact, at very close range (\<2.7 Å), may further stabilize the AcrF8–Cascade binding, essentially “locking” AcrF8 into the complex[\[23\]](https://pmc.ncbi.nlm.nih.gov/articles/PMC7132274/#:~:text=AcrF8%20%28Fig,crRNA%20hybrid%20%28Fig.%203%20B). Together, these structural features explain how AcrF8 achieves a tight and specific association with the Type I-F Cascade: one face of AcrF8 (encompassing part of its β-sheet/loop and one helix) is customized to fit into a cavity of the Cascade and engage both the protein components (Cas5f/Cas7f/Cas8f) and the crRNA. Importantly, **AcrF8 is not an enzyme** – it does not chemically modify Cas proteins or DNA/RNA – rather, its fold creates a physical blockade. This contrasts with a few other anti-CRISPRs (e.g. AcrIF11, which *enzymatically* ADP-ribosylates a Cas protein to inactivate the complex[\[24\]](https://www.cell.com/molecular-cell/fulltext/S1097-2765\(20\)30645-6#:~:text=Our%20biochemical%20and%20structural%20data,of%20the%20critical%20PAM))[\[25\]](https://www.frontiersin.org/journals/bioengineering-and-biotechnology/articles/10.3389/fbioe.2020.575393/full#:~:text=,DNA%20by%20binding%20different). AcrF8’s inhibition is purely through **steric and allosteric interference**: by occupying a critical binding pocket and clamping onto the crRNA, it prevents the CRISPR-Cas machinery from recognizing or cutting the target DNA. The specificity of AcrF8 for Type I-F systems is reflected in the co-evolution of its interface – the protein is tailored to the particular Cascade architecture of I-F (for instance, the spacing of Cas7f subunits and crRNA length in Pectobacterium/Pseudomonas Type I-F)[\[26\]](https://www.frontiersin.org/journals/bioengineering-and-biotechnology/articles/10.3389/fbioe.2020.575393/full#:~:text=DNA%20docking%20to%20the%20Csy,complex%20backbone%20at%20lysine%20residues)[\[27\]](https://www.frontiersin.org/journals/bioengineering-and-biotechnology/articles/10.3389/fbioe.2020.575393/full#:~:text=AcrIF8%20also%20interferes%20with%20crRNA,thumb%20domain%2C%20three%20crRNA%20bases). This specificity ensures that AcrF8 potently inhibits the host’s I-F CRISPR, but would not necessarily bind other types (e.g., Type I-E or II) which have different effector complex structures.

*Figure: Cryo-EM structural insights into AcrF8 function.* *(A)* *Overall architecture of the Type I-F* Cascade *(Csy) complex bound by one AcrF8 (gray). The Cascade is composed of Cas5f (green), Cas8f (orange), and a backbone of Cas7f subunits (blue tones) wrapped around the crRNA (yellow). AcrF8 inserts at the backbone, contacting multiple subunits.* *(B)* *Close-up view of AcrF8 (gray surface) nestled in a pocket formed by Cas5f, Cas7f, and Cas8f. AcrF8’s α-helix (red) docks against a positively charged groove on the Cascade (basic residues from Cas5f/Cas7f/Cas8f highlighted in magenta)[\[22\]](https://pmc.ncbi.nlm.nih.gov/articles/PMC7132274/#:~:text=surrounded%20by%20Cas5f%2C%20Cas7,4%20%C3%85%2C%20which%20is%20close). AcrF8 also interacts directly with the crRNA (dashed red lines): residues T29 and A32 in AcrF8 (purple) are positioned adjacent to crRNA bases U\_+21–G\_+23 (yellow), blocking that segment of the RNA[\[11\]](https://pmc.ncbi.nlm.nih.gov/articles/PMC7132274/#:~:text=residue,crRNA%20hybridization%20and).* *(C)* *Diagram of the AcrF8–crRNA interface (another angle), illustrating how AcrF8’s binding (purple loop/helix) creates a four-nucleotide* dead zone *(red bracket) on the crRNA where base-pairing to invading DNA is prevented.* *(D)* *Functional assay of AcrF8 mutants: An in vitro DNA cleavage gel showing that wild-type AcrF8 completely inhibits DNA cutting by Cas3 (no product band), whereas AcrF8 mutants I31A and A32G (lacking key crRNA-contact residues) fail to fully block Cas3 (cleavage products appear, arrows), resulting in restored DNA cleavage[\[15\]](https://pmc.ncbi.nlm.nih.gov/articles/PMC7132274/#:~:text=by%20the%20thumb%20of%20Cas7,we%20also%20observed%20interactions%20between). This confirms that AcrF8’s interaction with those crRNA bases is essential for its anti-CRISPR activity.*[\[10\]](https://pmc.ncbi.nlm.nih.gov/articles/PMC7132274/#:~:text=AcrF8%20is%20a%2092,4%20%C3%85%2C%20which%20is%20close)[\[14\]](https://pmc.ncbi.nlm.nih.gov/articles/PMC7132274/#:~:text=C%29,we%20also%20observed%20interactions%20between)

## Regulation of acrF8 Expression (Acr–Aca Operon)

Because anti-CRISPR proteins can compromise the host’s immunity even after phage infection, their expression is often tightly controlled. In phage ZF40, **acrIF8 is co-expressed with a dedicated transcriptional repressor, Aca2**, which regulates the timing and level of AcrF8 production[\[3\]](https://pmc.ncbi.nlm.nih.gov/articles/PMC8434428/#:~:text=et%20al,CRISPR%20production). The acrIF8–aca2 genes form an operon with a single promoter upstream of acrIF8[\[28\]](https://pmc.ncbi.nlm.nih.gov/articles/PMC8434428/#:~:text=Structure%20of%20Aca2,CTD). Aca2 (Anti-CRISPR associated protein 2\) is a **helix-turn-helix (HTH) DNA-binding protein** that binds to operator sites in this promoter to auto-repress the operon[\[3\]](https://pmc.ncbi.nlm.nih.gov/articles/PMC8434428/#:~:text=et%20al,CRISPR%20production)[\[29\]](https://academic.oup.com/nar/article/50/15/8919/6654409#:~:text=Molecular%20basis%20of%20anti,promoter%20of%20acr%20genes%2C). In other words, Aca2 acts as an autoregulator: it prevents transcription of its own operon (thus keeping acrF8 off) until conditions favor anti-CRISPR expression. The promoter region of acrIF8-aca2 contains two inverted repeat sequences (designated IR1 and IR2) that serve as Aca2 binding sites[\[28\]](https://pmc.ncbi.nlm.nih.gov/articles/PMC8434428/#:~:text=Structure%20of%20Aca2,CTD). Biochemical and genetic evidence indicates that Aca2 primarily binds with high affinity to the first repeat (IR1) and this interaction is crucial for repression in vivo[\[30\]](https://www.researchgate.net/figure/Aca2-represses-the-acrIF8-aca2-operon-A-Schematic-of-the-plasmid-setup-for-the-assay_fig2_335311009#:~:text=Context%208)[\[31\]](https://www.researchgate.net/figure/Aca2-represses-the-acrIF8-aca2-operon-A-Schematic-of-the-plasmid-setup-for-the-assay_fig2_335311009#:~:text=,). Disruption of the IR1 sequence greatly impairs Aca2-mediated repression of the operon, whereas IR2 appears to be secondary or redundant in function[\[30\]](https://www.researchgate.net/figure/Aca2-represses-the-acrIF8-aca2-operon-A-Schematic-of-the-plasmid-setup-for-the-assay_fig2_335311009#:~:text=Context%208)[\[31\]](https://www.researchgate.net/figure/Aca2-represses-the-acrIF8-aca2-operon-A-Schematic-of-the-plasmid-setup-for-the-assay_fig2_335311009#:~:text=,). Aca2 functions as a dimer, and its recently solved crystal structure shows it has a two-domain architecture: an N-terminal HTH domain for sequence-specific DNA binding, and a C-terminal dimerization domain that is distinct from other repressors[\[32\]](https://pmc.ncbi.nlm.nih.gov/articles/PMC8434428/#:~:text=report%20the%20first%20structure%20of,a%20more%20widespread%20family%20of). Dimerization aligns the two HTH motifs such that Aca2 can bind as a homodimer to the palindromic IR1/IR2 operator sites, inserting its “recognition” helices into the DNA major grooves[\[32\]](https://pmc.ncbi.nlm.nih.gov/articles/PMC8434428/#:~:text=report%20the%20first%20structure%20of,a%20more%20widespread%20family%20of)[\[28\]](https://pmc.ncbi.nlm.nih.gov/articles/PMC8434428/#:~:text=Structure%20of%20Aca2,CTD). This blocks RNA polymerase from accessing the acrIF8 promoter, thereby silencing transcription.

**Physiologically, how is acrF8 expression controlled?** During the normal lysogenic state (when phage ZF40’s genome is integrated in the bacterial chromosome), Aca2 is expressed at a low basal level that is sufficient to keep the acrIF8-aca2 operon shut off[\[33\]](https://www.researchgate.net/figure/Aca2-represses-the-acrIF8-aca2-operon-A-Schematic-of-the-plasmid-setup-for-the-assay_fig2_335311009#:~:text=,aca2%20operon.). In fact, experiments with *P. carotovorum* lysogens showed that the presence of the ZF40 prophage (which naturally produces Aca2) causes strong repression of an acrIF8 promoter reporter, whereas strains lacking the prophage (no Aca2) show high promoter activity[\[33\]](https://www.researchgate.net/figure/Aca2-represses-the-acrIF8-aca2-operon-A-Schematic-of-the-plasmid-setup-for-the-assay_fig2_335311009#:~:text=,aca2%20operon.)[\[34\]](https://www.researchgate.net/figure/Aca2-represses-the-acrIF8-aca2-operon-A-Schematic-of-the-plasmid-setup-for-the-assay_fig2_335311009#:~:text=,aca2%20promoter.). This indicates that *in vivo* there is always a trickle of Aca2 made from the prophage, enough to maintain AcrF8 at nearly zero levels during lysogeny[\[33\]](https://www.researchgate.net/figure/Aca2-represses-the-acrIF8-aca2-operon-A-Schematic-of-the-plasmid-setup-for-the-assay_fig2_335311009#:~:text=,aca2%20operon.). The benefit of this is clear: the bacterium’s own CRISPR-Cas system remains active most of the time, which likely helps the lysogen fend off other invading phages or plasmids. The phage only needs to deploy AcrF8 when it initiates an infection or enters the lytic cycle. Indeed, a regulatory “burst” appears to occur upon phage induction: the acrIF8 promoter is intrinsically strong and drives high acrIF8 transcription immediately after phage DNA enters a host (before Aca2 accumulates), ensuring AcrF8 is produced at the critical moment to counter host immunity[\[35\]](https://pmc.ncbi.nlm.nih.gov/articles/PMC6754177/#:~:text=,that%20Aca%20proteins%20subsequently). Shortly thereafter, Aca2 (whose gene is co-transcribed) accumulates and feeds back to shut off further acrIF8 expression[\[35\]](https://pmc.ncbi.nlm.nih.gov/articles/PMC6754177/#:~:text=,that%20Aca%20proteins%20subsequently)[\[3\]](https://pmc.ncbi.nlm.nih.gov/articles/PMC8434428/#:~:text=et%20al,CRISPR%20production). This feedback loop produces a pulse of AcrF8 sufficient to neutralize CRISPR-Cas during the phage’s vulnerable stage, but avoids unnecessary prolonged AcrF8 expression. In a sense, Aca2 provides a **fail-safe mechanism**: once the phage has established itself (e.g. as a prophage), AcrF8 is no longer needed and is repressed to allow the host’s CRISPR system to resume normal function until the next phage induction.

Experimental studies have corroborated this regulatory model. In a plasmid-based reporter assay, the acrIF8-aca2 promoter drove strong expression of a fluorescent protein when Aca2 was absent, but **expression was dramatically repressed when Aca2 was supplied**, confirming that Aca2 directly shuts down the operon[\[34\]](https://www.researchgate.net/figure/Aca2-represses-the-acrIF8-aca2-operon-A-Schematic-of-the-plasmid-setup-for-the-assay_fig2_335311009#:~:text=,aca2%20promoter.)[\[36\]](https://www.researchgate.net/figure/Aca2-represses-the-acrIF8-aca2-operon-A-Schematic-of-the-plasmid-setup-for-the-assay_fig2_335311009#:~:text=,ure%201A%29.). Furthermore, point mutations in Aca2’s HTH that abolish DNA binding, or mutations in the promoter IR sequences, abolish repression, leading to unregulated acrIF8 transcription[\[37\]](https://www.researchgate.net/figure/Aca2-represses-the-acrIF8-aca2-operon-A-Schematic-of-the-plasmid-setup-for-the-assay_fig2_335311009#:~:text=,ure%201A%29.)[\[38\]](https://www.researchgate.net/figure/Aca2-represses-the-acrIF8-aca2-operon-A-Schematic-of-the-plasmid-setup-for-the-assay_fig2_335311009#:~:text=,). Such unregulated anti-CRISPR production can be detrimental: if AcrF8 were expressed at the wrong time, it could disable the host’s CRISPR defenses and leave the cell open to attack by other phages. Consistent with this, **Aca2-mediated control is crucial for phage ZF40’s fitness**. If the entire acrIF8–aca2 operon is deleted from the phage, or if Aca2 is not functioning, ZF40 cannot effectively propagate in a CRISPR-enabled host[\[39\]](https://www.liebertpub.com/doi/full/10.1089/crispr.2024.0047?doi=10.1089/crispr.2024.0047#:~:text=,replication%2C%20and%20that%20recombination)[\[40\]](https://www.jbc.org/article/S0021-9258\(24\)00209-6/pdf#:~:text=Abstract%201339%20Genetic%20and%20Phenotypic,applied%20a%20recombination%20and). The phage would be quickly eliminated by the bacterial immune system without its anti-CRISPR “shield.” Thus, phage ZF40 has evolved the acrIF8/Aca2 module as a finely tuned counter-defense system: AcrF8 provides the immediate immunosuppression needed during infection, and Aca2 ensures this counter-attack is kept on a short leash. Intriguingly, recent research suggests that bacteria might sometimes fight back by using their own analogs of Aca proteins to inhibit phage anti-CRISPR operons[\[41\]](https://pmc.ncbi.nlm.nih.gov/articles/PMC8434428/#:~:text=turn,2019) – effectively an “anti-anti-CRISPR” strategy by the host. This ongoing arms race underlines the delicate balance: phage ZF40 must deploy AcrF8 to survive host CRISPR, but it must also regulate AcrF8 (via Aca2) to avoid undermining the host’s immunity more than necessary or at inappropriate times.

In summary, **AcrF8 is a phage-encoded anti-CRISPR protein that inhibits Type I-F CRISPR-Cas** by binding the Cascade complex and blocking crRNA–DNA hybridization. Its **structure** (a compact α/β fold) is specialized for inserting into the Cascade and contacting the crRNA, thereby sterically preventing the DNA target from being recognized. Key residues on AcrF8 form a patch that **locks onto the crRNA and Cascade proteins**, making AcrF8’s inhibition highly potent and specific. The phage tightly **regulates AcrF8 via the Aca2 repressor**: acrF8 is expressed only when the phage is actively combating the host’s CRISPR system, and is turned off during dormancy. This ensures that phage ZF40 gains the necessary protection from CRISPR-Cas when it matters most (during infection or induction), while minimizing fitness costs to the lysogen. AcrF8, together with its regulator Aca2, exemplifies the sophisticated molecular arms race between bacteriophages and bacteria – a fine-tuned offensive countermeasure matched by equally nuanced control. Such insights into AcrF8’s mechanism and regulation not only deepen our understanding of phage biology, but also inform potential biotechnological uses of anti-CRISPRs in controlling CRISPR-Cas systems for research and therapeutic applications[\[42\]](https://journals.asm.org/doi/10.1128/msystems.00817-22#:~:text=Error%20fetching)[\[43\]](https://www.sciencedirect.com/science/article/pii/S1097276522004373#:~:text=Anti,Cas%20systems).

**Sources:** The information above is synthesized from structural and biochemical studies of AcrF8[\[10\]](https://pmc.ncbi.nlm.nih.gov/articles/PMC7132274/#:~:text=AcrF8%20is%20a%2092,4%20%C3%85%2C%20which%20is%20close)[\[13\]](https://pmc.ncbi.nlm.nih.gov/articles/PMC7132274/#:~:text=nucleotides%20%28U,we%20also%20observed%20interactions%20between), as well as genetic and genomic analyses of the acrIF8–aca2 operon in phage ZF40[\[33\]](https://www.researchgate.net/figure/Aca2-represses-the-acrIF8-aca2-operon-A-Schematic-of-the-plasmid-setup-for-the-assay_fig2_335311009#:~:text=,aca2%20operon.)[\[3\]](https://pmc.ncbi.nlm.nih.gov/articles/PMC8434428/#:~:text=et%20al,CRISPR%20production). These include a 2020 cryo-EM study resolving AcrF8 bound to Cascade[\[9\]](https://pmc.ncbi.nlm.nih.gov/articles/PMC7132274/#:~:text=AcrF8%20is%20a%2092,just%20after%20the%20kink%20caused), a 2019/2021 series of studies on Aca2-mediated operon repression[\[33\]](https://www.researchgate.net/figure/Aca2-represses-the-acrIF8-aca2-operon-A-Schematic-of-the-plasmid-setup-for-the-assay_fig2_335311009#:~:text=,aca2%20operon.)[\[28\]](https://pmc.ncbi.nlm.nih.gov/articles/PMC8434428/#:~:text=Structure%20of%20Aca2,CTD), and broader reviews on anti-CRISPR mechanisms[\[27\]](https://www.frontiersin.org/journals/bioengineering-and-biotechnology/articles/10.3389/fbioe.2020.575393/full#:~:text=AcrIF8%20also%20interferes%20with%20crRNA,thumb%20domain%2C%20three%20crRNA%20bases)[\[29\]](https://academic.oup.com/nar/article/50/15/8919/6654409#:~:text=Molecular%20basis%20of%20anti,promoter%20of%20acr%20genes%2C). Together, these sources provide a comprehensive picture of AcrF8’s function, domain architecture, and regulatory control in the context of phage ZF40 and its Pectobacterium host.

---

[\[1\]](https://en.wikipedia.org/wiki/Anti-CRISPR#:~:text=AcrF8%20%20AcrF8%20ZF40%20,II%E2%80%91A%20%20149) [\[4\]](https://en.wikipedia.org/wiki/Anti-CRISPR#:~:text=After%20some%20studies%2C%20a%20similar,6) [\[5\]](https://en.wikipedia.org/wiki/Anti-CRISPR#:~:text=to%20their%20genomic%20proximity%3A%20AcrF6%2C,6) Anti-CRISPR \- Wikipedia

[https://en.wikipedia.org/wiki/Anti-CRISPR](https://en.wikipedia.org/wiki/Anti-CRISPR)

[\[2\]](https://www.liebertpub.com/doi/10.1089/crispr.2024.0047#:~:text=,replication%2C%20and%20that%20recombination) Repurposing an Endogenous CRISPR-Cas System to Generate and ...

[https://www.liebertpub.com/doi/10.1089/crispr.2024.0047](https://www.liebertpub.com/doi/10.1089/crispr.2024.0047)

[\[3\]](https://pmc.ncbi.nlm.nih.gov/articles/PMC8434428/#:~:text=et%20al,CRISPR%20production) [\[28\]](https://pmc.ncbi.nlm.nih.gov/articles/PMC8434428/#:~:text=Structure%20of%20Aca2,CTD) [\[32\]](https://pmc.ncbi.nlm.nih.gov/articles/PMC8434428/#:~:text=report%20the%20first%20structure%20of,a%20more%20widespread%20family%20of) [\[41\]](https://pmc.ncbi.nlm.nih.gov/articles/PMC8434428/#:~:text=turn,2019)  Crystal structure of the anti-CRISPR repressor Aca2 \- PMC 

[https://pmc.ncbi.nlm.nih.gov/articles/PMC8434428/](https://pmc.ncbi.nlm.nih.gov/articles/PMC8434428/)

[\[6\]](https://pmc.ncbi.nlm.nih.gov/articles/PMC7132274/#:~:text=proteins%20bind%20differently%20to%20the,F%20CRISPR%E2%80%93Cas%20system) [\[7\]](https://pmc.ncbi.nlm.nih.gov/articles/PMC7132274/#:~:text=I%20CRISPR%E2%80%93Cas%20systems%20are%20further,complex%20is%20comprised%20of%20four) [\[8\]](https://pmc.ncbi.nlm.nih.gov/articles/PMC7132274/#:~:text=types%20of%20Cas%20proteins%20%28Cas5f,1%7D%20%284) [\[9\]](https://pmc.ncbi.nlm.nih.gov/articles/PMC7132274/#:~:text=AcrF8%20is%20a%2092,just%20after%20the%20kink%20caused) [\[10\]](https://pmc.ncbi.nlm.nih.gov/articles/PMC7132274/#:~:text=AcrF8%20is%20a%2092,4%20%C3%85%2C%20which%20is%20close) [\[11\]](https://pmc.ncbi.nlm.nih.gov/articles/PMC7132274/#:~:text=residue,crRNA%20hybridization%20and) [\[12\]](https://pmc.ncbi.nlm.nih.gov/articles/PMC7132274/#:~:text=nucleotides%20%28U,this%20hypothesis%2C%20we%20recombinantly%20expressed) [\[13\]](https://pmc.ncbi.nlm.nih.gov/articles/PMC7132274/#:~:text=nucleotides%20%28U,we%20also%20observed%20interactions%20between) [\[14\]](https://pmc.ncbi.nlm.nih.gov/articles/PMC7132274/#:~:text=C%29,we%20also%20observed%20interactions%20between) [\[15\]](https://pmc.ncbi.nlm.nih.gov/articles/PMC7132274/#:~:text=by%20the%20thumb%20of%20Cas7,we%20also%20observed%20interactions%20between) [\[19\]](https://pmc.ncbi.nlm.nih.gov/articles/PMC7132274/#:~:text=Our%20near,the%20big%20difference%20being%20in) [\[20\]](https://pmc.ncbi.nlm.nih.gov/articles/PMC7132274/#:~:text=The%20100,Cas8f%20has%20been%20shown%20to) [\[21\]](https://pmc.ncbi.nlm.nih.gov/articles/PMC7132274/#:~:text=structures%20shows%20that%20they%20share,hydrophobic%20surface%20to%20promote%20the) [\[22\]](https://pmc.ncbi.nlm.nih.gov/articles/PMC7132274/#:~:text=surrounded%20by%20Cas5f%2C%20Cas7,4%20%C3%85%2C%20which%20is%20close) [\[23\]](https://pmc.ncbi.nlm.nih.gov/articles/PMC7132274/#:~:text=AcrF8%20%28Fig,crRNA%20hybrid%20%28Fig.%203%20B)  Inhibition mechanisms of AcrF9, AcrF8, and AcrF6 against type I-F CRISPR–Cas complex revealed by cryo-EM \- PMC 

[https://pmc.ncbi.nlm.nih.gov/articles/PMC7132274/](https://pmc.ncbi.nlm.nih.gov/articles/PMC7132274/)

[\[16\]](https://www.frontiersin.org/journals/bioengineering-and-biotechnology/articles/10.3389/fbioe.2020.575393/full#:~:text=AcrIF8,of%20AcrIF4%20is%20still%20unknown) [\[17\]](https://www.frontiersin.org/journals/bioengineering-and-biotechnology/articles/10.3389/fbioe.2020.575393/full#:~:text=are%20Cas7%20,work%20by%20mimicking%20the) [\[18\]](https://www.frontiersin.org/journals/bioengineering-and-biotechnology/articles/10.3389/fbioe.2020.575393/full#:~:text=subunits%20can%20share%20similar%20inhibitory,work%20by%20mimicking%20the) [\[25\]](https://www.frontiersin.org/journals/bioengineering-and-biotechnology/articles/10.3389/fbioe.2020.575393/full#:~:text=,DNA%20by%20binding%20different) [\[26\]](https://www.frontiersin.org/journals/bioengineering-and-biotechnology/articles/10.3389/fbioe.2020.575393/full#:~:text=DNA%20docking%20to%20the%20Csy,complex%20backbone%20at%20lysine%20residues) [\[27\]](https://www.frontiersin.org/journals/bioengineering-and-biotechnology/articles/10.3389/fbioe.2020.575393/full#:~:text=AcrIF8%20also%20interferes%20with%20crRNA,thumb%20domain%2C%20three%20crRNA%20bases) Frontiers | Types I and V Anti-CRISPR Proteins: From Phage Defense to Eukaryotic Synthetic Gene Circuits

[https://www.frontiersin.org/journals/bioengineering-and-biotechnology/articles/10.3389/fbioe.2020.575393/full](https://www.frontiersin.org/journals/bioengineering-and-biotechnology/articles/10.3389/fbioe.2020.575393/full)

[\[24\]](https://www.cell.com/molecular-cell/fulltext/S1097-2765\(20\)30645-6#:~:text=Our%20biochemical%20and%20structural%20data,of%20the%20critical%20PAM) A Type I-F Anti-CRISPR Protein Inhibits the CRISPR-Cas ...

[https://www.cell.com/molecular-cell/fulltext/S1097-2765(20)30645-6](https://www.cell.com/molecular-cell/fulltext/S1097-2765\(20\)30645-6)

[\[29\]](https://academic.oup.com/nar/article/50/15/8919/6654409#:~:text=Molecular%20basis%20of%20anti,promoter%20of%20acr%20genes%2C) Molecular basis of anti-CRISPR operon repression by Aca10

[https://academic.oup.com/nar/article/50/15/8919/6654409](https://academic.oup.com/nar/article/50/15/8919/6654409)

[\[30\]](https://www.researchgate.net/figure/Aca2-represses-the-acrIF8-aca2-operon-A-Schematic-of-the-plasmid-setup-for-the-assay_fig2_335311009#:~:text=Context%208) [\[31\]](https://www.researchgate.net/figure/Aca2-represses-the-acrIF8-aca2-operon-A-Schematic-of-the-plasmid-setup-for-the-assay_fig2_335311009#:~:text=,) [\[33\]](https://www.researchgate.net/figure/Aca2-represses-the-acrIF8-aca2-operon-A-Schematic-of-the-plasmid-setup-for-the-assay_fig2_335311009#:~:text=,aca2%20operon.) [\[34\]](https://www.researchgate.net/figure/Aca2-represses-the-acrIF8-aca2-operon-A-Schematic-of-the-plasmid-setup-for-the-assay_fig2_335311009#:~:text=,aca2%20promoter.) [\[36\]](https://www.researchgate.net/figure/Aca2-represses-the-acrIF8-aca2-operon-A-Schematic-of-the-plasmid-setup-for-the-assay_fig2_335311009#:~:text=,ure%201A%29.) [\[37\]](https://www.researchgate.net/figure/Aca2-represses-the-acrIF8-aca2-operon-A-Schematic-of-the-plasmid-setup-for-the-assay_fig2_335311009#:~:text=,ure%201A%29.) [\[38\]](https://www.researchgate.net/figure/Aca2-represses-the-acrIF8-aca2-operon-A-Schematic-of-the-plasmid-setup-for-the-assay_fig2_335311009#:~:text=,) Aca2 represses the acrIF8-aca2 operon. (A) Schematic of the plasmid... | Download Scientific Diagram

[https://www.researchgate.net/figure/Aca2-represses-the-acrIF8-aca2-operon-A-Schematic-of-the-plasmid-setup-for-the-assay\_fig2\_335311009](https://www.researchgate.net/figure/Aca2-represses-the-acrIF8-aca2-operon-A-Schematic-of-the-plasmid-setup-for-the-assay_fig2_335311009)

[\[35\]](https://pmc.ncbi.nlm.nih.gov/articles/PMC6754177/#:~:text=,that%20Aca%20proteins%20subsequently) Anti-CRISPR Associated Proteins are Crucial Repressors of Anti ...

[https://pmc.ncbi.nlm.nih.gov/articles/PMC6754177/](https://pmc.ncbi.nlm.nih.gov/articles/PMC6754177/)

[\[39\]](https://www.liebertpub.com/doi/full/10.1089/crispr.2024.0047?doi=10.1089/crispr.2024.0047#:~:text=,replication%2C%20and%20that%20recombination) Repurposing an Endogenous CRISPR-Cas System to Generate and ...

[https://www.liebertpub.com/doi/full/10.1089/crispr.2024.0047?doi=10.1089/crispr.2024.0047](https://www.liebertpub.com/doi/full/10.1089/crispr.2024.0047?doi=10.1089/crispr.2024.0047)

[\[40\]](https://www.jbc.org/article/S0021-9258\(24\)00209-6/pdf#:~:text=Abstract%201339%20Genetic%20and%20Phenotypic,applied%20a%20recombination%20and) Abstract 1339 Genetic and Phenotypic Equivalence Between Two ...

[https://www.jbc.org/article/S0021-9258(24)00209-6/pdf](https://www.jbc.org/article/S0021-9258\(24\)00209-6/pdf)

[\[42\]](https://journals.asm.org/doi/10.1128/msystems.00817-22#:~:text=Error%20fetching) journals.asm.org

[https://journals.asm.org/doi/10.1128/msystems.00817-22](https://journals.asm.org/doi/10.1128/msystems.00817-22)

[\[43\]](https://www.sciencedirect.com/science/article/pii/S1097276522004373#:~:text=Anti,Cas%20systems) Anti-CRISPR prediction using deep learning reveals an inhibitor of ...

[https://www.sciencedirect.com/science/article/pii/S1097276522004373](https://www.sciencedirect.com/science/article/pii/S1097276522004373)